“The Terasaki Institute leads the world in the development of bioprintable, biopolymer-based technologies poised to revolutionize drug delivery, wearable and implantable devices. Jointly with HTL we expect to bring to life a new generation of biopolymer-based applications in critical sectors of precision and regenerative medicine,” added Maurizio Vecchione, Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation.

Read more below.



To see our most recent news,
follow us on LinkedIn

Go to our LinkedIn page